Therachon
WebbVP Biology at Therachon. Location: Basel, Canton of Basel-Stadt, Switzerland. Dr. Jeffrey Stavenhagen brings 20 years of scientific leadership experience in both the US and … http://theracion.com/
Therachon
Did you know?
WebbTherachon is a global biotechnology company focused on developing medicines for rare, genetic diseases that currently have no available treatments. The company’s lead … Webbtherachon.com
Webb25 mars 2024 · Therachon is committed to making a difference in the lives of patients living with serious rare disorders. For more information, please visit … Webb30 jan. 2024 · BASEL, Switzerland, Jan. 30, 2024 /PRNewswire/ -- Therachon AG ("Therachon"), a clinical-stage biotechnology company focused on the discovery, development and commercialization of innovative ...
WebbTherachon 1,172 followers on LinkedIn. Life-Transforming Therapies - Developing novel therapeutics for serious rare conditions Therachon is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare conditions for which there is significant unmet medical need. Webb9 maj 2024 · May 9, 2024 - Updated on June 24, 2024. 2 minutes. Pharma giant Pfizer is acquiring the Swiss biotech Therachon, which is developing a protein drug to boost bone growth in the genetic condition achondroplasia. Pfizer will pay €303M ($340M) upfront, and up to €420M ($470M) dependent on Therachon reaching milestones in the development …
WebbTherachon General Information. Description. Developer of novel therapeutics intended to facilitate treatment for rare genetic diseases. The company develops pipeline of therapeutics focused on rare gastrointestinal and musculoskeletal disorders and conditions, enabling medical practitioners to treat patients with short bowel syndrome …
Webb8 jan. 2024 · The founders of Swiss biotech Therachon have launched a new company called VectivBio, also based in Basel, with €31M funding to develop drugs for rare … great hunting bowsWebb29 aug. 2024 · About Therachon. Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases that currently have no available treatments. The company’s lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of short-limbed dwarfism. great hunting gearWebb17 maj 2024 · Therachon is a clinical-stage global biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare conditions for which there is ... great hunting camp ideasWebbDevelopment group, serving as its Global Head for Integration Management and Global Head of Alliance Management. His work included the integration of Wyeth, Hospira, Anacor, Medivation, Therachon, Array and most recently Amplyx. He also directly led the separation of. 09 Apr 2024 21:53:51 floating heads animeWebbPfizer is set to pay $340 million (€304 million) upfront to buy Therachon for Pfizer is set to pay $340 million (€304 million) upfront to buy Therachon for its treatment for a form of … great hunting creek vahttp://therachon.com/research/ great hunting christmas giftsWebb6 nov. 2024 · Key operating players in global achondroplasia treatment market are Ascendis Pharma A/S, BridgeBio Pharma, Inc., QED Therapeutics, BioMarin Pharmaceutical Inc., Pfizer Inc., Therachon Holding AG, and RIBOMIC Inc. Market Taxonomy: On the basis of drug class, the global achondroplasia treatment market is segmented into: Lipase … floating heads book covers